Sony Mobile and LG are backing it. Lenovo is considering joining in. And Qualcomm has a trial in place. Everyone at CES 2014 was talking about their wearables strategy.

Using wearable devices to track health and fitness data was a major theme at this year’s event, as evidenced by the number of announcements by vendors.

Sony Mobile became the latest vendor to jump on the wearables bandwagon, with Kunimasa Suzuki, president and CEO, describing such products as “an important part of our future”, featuring alongside the announcement of traditional frontline smartphone announcements.

The company outlined its “smartWear experience vision”, which comprises an upcoming range of so-called smartWear products, with Xperia smartphones, and a new Lifelog application. Leading the way is a SmartBand (pictured) which “offers life empowerment by logging daily activities and representing them visually in Sony’s Lifelog application”.

And rival LG announced a move into the fitness wearables space with its new Lifeband Touch product, an activity-tracking wristband that collects fitness data.

“Wearable tech is going to be huge at this year’s CES and we are happy to get the ball rolling,” said an LG exec before introducing the new device. In addition, it was touting its new Heart Rate Earphones.

Lifeband Touch and Heart Rate Earphones will be available starting in the US in the first half of 2014, to be followed by rollouts in other markets.

Meanwhile Jay Parker, president of Lenovo North America, told Re/code that the company is in the “strategy development” phase of wearable computing.

“We’re talking about it internally and trying to develop our viewpoint on it,” he said in an interview. However, Parker was sceptical about the immediate impact of wearables. “I don’t think [wearables] will be very relevant and mainstream for the next couple years, but we’re interested to see where it goes and what we can do with that.”

Finally, Qualcomm actually has some activity on the ground, not just announcements and positive noises. And the company’s trial is of a more ambitious kind than simply developing a device. It is running a trial that involves injections into your bloodstream that can warn a person two weeks before they are likely to get a heartattack. “Wearables won’t just be outside your body, they will be inside,” said CEO Paul Jacobs.